Department of Health Sciences, University of York, York, United Kingdom.
Queens Centre for Oncology and Haematology, Castle Hill Hospital, Cottingham, United Kingdom.
PLoS One. 2022 Feb 10;17(2):e0263672. doi: 10.1371/journal.pone.0263672. eCollection 2022.
Most blood cancers are incurable and typically follow unpredictable remitting-relapsing pathways associated with varying need for treatment, which may be distressing for patients. Our objective was to conduct a qualitative study to explore understanding among patients with such malignancies, including the explanations given by HCPs and the impact of uncertain trajectories, to generate evidence that could guide improvements in clinical practice.
The study is set within a population-based patient cohort (the Haematological Malignancy Research Network), in which care is delivered across 14 hospitals according to national guidelines. In-depth interviews were conducted with 35 patients with chronic lymphocytic leukaemia, follicular lymphoma, marginal zone lymphoma or myeloma; and 10 accompanying relatives. Purposive sampling ensured selection of information-rich participants and the data were interrogated using reflective thematic analysis.
Rich data were collected and four themes (11 sub-themes) were identified: 1) Knowledge and understanding of chronic haematological malignancies; 2) Incurable but treatable; 3) Uncertainty about the future; and 4) Treatable (but still incurable): Impact on patients. Patients had rarely heard of blood cancer and many expressed difficulty understanding how an incurable malignancy that could not be removed, was treatable, often for long periods. While some were reassured that their cancer did not pose an immediate survival threat, others were particularly traumatised by the uncertain future it entailed, suffering ongoing emotional distress as a result, which could be more burdensome than any physical symptoms. Nonetheless, most interviewees understood that uncertain pathways were caused by the unpredictability of their disease trajectory, and not information being withheld.
Many participants lacked knowledge about chronic haematological malignancies. HCPs acted to reassure patients about their diagnosis, and while this was appropriate and effective for some, it was less so for others, as the cancer-impact involved struggling to cope with ongoing uncertainty, distress and a shortened life-span.
大多数血液癌症是无法治愈的,通常遵循不可预测的缓解-复发途径,与治疗需求的变化相关,这可能令患者感到痛苦。我们的目的是进行一项定性研究,以探索患有此类恶性肿瘤的患者的理解,包括 HCP 提供的解释以及不确定轨迹的影响,以生成可能指导临床实践改进的证据。
该研究在基于人群的患者队列(血液恶性肿瘤研究网络)中进行,根据国家指南,在 14 家医院提供护理。对 35 名患有慢性淋巴细胞白血病、滤泡性淋巴瘤、边缘区淋巴瘤或骨髓瘤的患者以及 10 名随行亲属进行了深入访谈。有目的的抽样确保了信息丰富的参与者的选择,并且使用反思性主题分析来检查数据。
收集了丰富的数据,并确定了四个主题(11 个子主题):1)对慢性血液病的认识;2)不可治愈但可治疗;3)对未来的不确定性;4)可治疗(但仍不可治愈):对患者的影响。患者很少听说过血液癌,许多人表示很难理解为什么一种无法切除的、不可治愈的恶性肿瘤可以治疗,而且通常可以治疗很长时间。虽然有些人感到放心,因为他们的癌症不会对他们的生存构成直接威胁,但其他人特别受到其不确定未来的创伤,因此持续遭受情绪困扰,这可能比任何身体症状都更具负担。尽管如此,大多数受访者都明白,不确定的途径是由疾病轨迹的不可预测性引起的,而不是信息被隐瞒。
许多参与者缺乏对慢性血液病的了解。卫生保健提供者采取行动让患者对他们的诊断感到安心,虽然这对一些人是适当和有效的,但对其他人则不然,因为癌症的影响涉及努力应对持续的不确定性、痛苦和缩短的寿命。